Cartesian Therapeutics’ experimental cell therapy Descartes-08 outperformed a placebo at easing symptoms of generalized myasthenia gravis (gMG) in patients who test positive for self-reactive antibodies targeting the acetylcholine receptor (AChR) protein. That’s according to a new subgroup analysis of the Phase 2b MG-001 clinical trial (NCT04146051). Previous…
News
Rystiggo (rozanolixizumab-noli) provides consistent symptom relief for people with generalized myasthenia gravis (gMG) across more than a dozen treatment cycles, according to a new analysis of clinical trial data. The approved UCB therapy is given as weekly subcutaneous, or under-the-skin, infusions in six-week cycles, with additional cycles…
At this year’s Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, researchers and clinicians are talking about the central role of patients, families, and caregivers in driving change for people living with neuromuscular diseases. Bionews, the parent company of this site, sat down with John F. Crowley, president and…
Johnson & Johnson (J&J) has launched a Phase 3b clinical trial to compare the efficacy of two approved treatments for generalized myasthenia gravis (gMG). The trial, dubbed EPIC (NCT07217587), is specifically testing J&J’s Imaavy (nipocalimab) against Argenx’s Vyvgart (efgartigimod) in adults with gMG who…
Recovery after a myasthenia gravis (MG) exacerbation — a flare up or sudden worsening of disease symptoms — may take many months, even with the newer treatment options now available to MG patients. That’s according to a small study in Germany that followed 12 people with MG, treated with…
People with myasthenia gravis (MG) have higher psychological distress, including depression and anxiety, more frequent sleep problems, and greater cognitive difficulties than healthy people, according to a study in Italy. In addition, more severe disease and treatment with higher doses of corticosteroids were independent predictors of psychiatric symptoms…
Four weekly under-the-skin injections of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) led to a marked reduction in double vision and drooping eyelids in adults with ocular myasthenia gravis (MG), according to top-line Phase 3 results. These findings come from the global Phase 3 ADAPT OCULUS clinical trial (NCT06558279),…
Next week, researchers, clinicians, industry leaders, and families will gather at the 2026 MDA Clinical & Scientific Conference, hosted by the Muscular Dystrophy Association (MDA), to discuss the latest advances in neuromuscular disease research and care. Ahead of the event, Bionews, the parent company of this site, sat…
While certain medications are typically avoided in myasthenia gravis (MG), a large-scale study from France suggests that cholesterol-lowering statins may actually reduce the overall risk of death in these patients. The research indicates that although statins can slightly increase the short-term chance of a severe symptom flare-up, their…
More than two-thirds of people with clinically stable myasthenia gravis (MG) have problems with disturbed sleep, with resulting negative effects on their quality of life, a survey study of hundreds of MG patients in China has found. Further, those with sleep problems were significantly more likely to have obstructive…
Recent Posts
- I had to bite my tongue when my twin told me about a risky home project
- In life with MG, even small battles can feel overwhelming
- MDA 2026: CAR T-cell therapy Descartes-08 eases MG symptoms
- Living with myasthenia gravis is a full-time job
- MDA 2026: New data show Rystiggo provides consistent relief in gMG